NEURODEVELOPMENTAL DISORDER WITH ATAXIC GAIT, ABSENT SPEECH, AND DECREASED CORTICAL WHITE MATTER
|
0.600 |
GeneticVariation
|
disease |
CLINVAR |
Recurrent De Novo Mutations Disturbing the GTP/GDP Binding Pocket of RAB11B Cause Intellectual Disability and a Distinctive Brain Phenotype.
|
29106825 |
2017 |
NEURODEVELOPMENTAL DISORDER WITH ATAXIC GAIT, ABSENT SPEECH, AND DECREASED CORTICAL WHITE MATTER
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
Recurrent De Novo Mutations Disturbing the GTP/GDP Binding Pocket of RAB11B Cause Intellectual Disability and a Distinctive Brain Phenotype.
|
29106825 |
2017 |
Waist-Hip Ratio
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Rectal Carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The ADORE trial (adjuvant oxaliplatin in rectal cancer) is a multicenter, randomized trial in patients with postoperative ypStage II (ypT3-4N0) or III (ypT<sub>any</sub>N1-2) rectal cancer after fluoropyrimidine-based preoperative CRT and TME.
|
31593484 |
2019 |
Neoplasm Metastasis
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
LN metastasis was significantly associated with RFS in both ypT0-2 and ypT3-4 disease, with a stronger association for ypT0-2 disease (hazard ratio, 3.473, 95% confidence interval, 2.058-5.261; P < .001 for ypT0-2 and hazard ratio, 2.038; 95% confidence interval, 1.601-2.684; P < .001 for ypT3-4, respectively).
|
31027968 |
2019 |
NEURODEVELOPMENTAL DISORDER WITH ATAXIC GAIT, ABSENT SPEECH, AND DECREASED CORTICAL WHITE MATTER
|
0.600 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Recurrent De Novo Mutations Disturbing the GTP/GDP Binding Pocket of RAB11B Cause Intellectual Disability and a Distinctive Brain Phenotype.
|
29106825 |
2017 |
NEURODEVELOPMENTAL DISORDER WITH ATAXIC GAIT, ABSENT SPEECH, AND DECREASED CORTICAL WHITE MATTER
|
0.600 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Recurrent De Novo Mutations Disturbing the GTP/GDP Binding Pocket of RAB11B Cause Intellectual Disability and a Distinctive Brain Phenotype.
|
29106825 |
2017 |
Intellectual Disability
|
0.310 |
Biomarker
|
group |
BEFREE |
Recurrent De Novo Mutations Disturbing the GTP/GDP Binding Pocket of RAB11B Cause Intellectual Disability and a Distinctive Brain Phenotype.
|
29106825 |
2017 |
Intellectual Disability
|
0.310 |
Biomarker
|
group |
GENOMICS_ENGLAND |
Recurrent De Novo Mutations Disturbing the GTP/GDP Binding Pocket of RAB11B Cause Intellectual Disability and a Distinctive Brain Phenotype.
|
29106825 |
2017 |
Intellectual Disability
|
0.310 |
Biomarker
|
group |
GENOMICS_ENGLAND |
Recurrent De Novo Mutations Disturbing the GTP/GDP Binding Pocket of RAB11B Cause Intellectual Disability and a Distinctive Brain Phenotype.
|
29106825 |
2017 |
HIV Infections
|
0.300 |
Biomarker
|
group |
CTD_human |
Host cell gene expression during human immunodeficiency virus type 1 latency and reactivation and effects of targeting genes that are differentially expressed in viral latency.
|
15308739 |
2004 |
HIV Coinfection
|
0.300 |
Biomarker
|
disease |
CTD_human |
Host cell gene expression during human immunodeficiency virus type 1 latency and reactivation and effects of targeting genes that are differentially expressed in viral latency.
|
15308739 |
2004 |
Congenital clubfoot
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Dystonia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Hyperopia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Microcephaly
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Muscle Spasticity
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Nystagmus
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Optic Atrophy
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Stereotyped Behavior
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Stereotypic Movement Disorder
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Strabismus
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Talipes cavus
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Gait, Unsteady
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Feeding difficulties
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|